title: KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis.
abstract: Developing effective treatments for chronic neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) has proven extremely difficult. ALS is universally fatal, characterized by progressive weakness due to the degeneration of upper and lower motor neurons, and leads eventually to respiratory failure which is the usual cause of death. Only a single treatment has been approved, the modestly effective nonspecific neuroprotectant Rilutek (riluzole; 2-amino-6-(trifluoromethoxy)benzothiazole). KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine dihydrochloride, RPPX], a synthetic amino-benzothiazole with demonstrated activity in maintaining mitochondrial function, is being developed as a treatment for ALS. It has proven to be effective in multiple in vitro and in vivo assays of neuroprotection, including the G93A-SOD1 mutant mouse model; however, its specific mechanism of action remains unknown. The potential of KNS-760604 as a treatment for ALS was first suggested by studies showing that its optical enantiomer, Mirapex[(6S)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine; pramipexole dihydrochloride; PPX], a high-affinity agonist at dopamine D2, D3, and D4 receptors, exhibits important neuroprotective properties independent of its dopamine receptor agonism. In cell-based assays, both RPPX and PPX reduce the production of reactive oxygen species (ROS), attenuate the activation of apoptotic pathways, and increase cell survival in response to a variety of neurotoxins. However, PPX has limited utility as a clinical neuroprotective agent because the drug concentrations required for neuroprotection would likely produce unacceptable dopaminergic side effects. RPPX, on the other hand, while possessing the same neuroprotective potential as PPX, is a much lower-affinity dopamine receptor agonist and may therefore be more useful in the treatment of ALS. This review will examine the data supporting the hypothesis that the RPPX may have therapeutic potential for the treatment of neurodegenerative disorders including ALS. In addition, we will briefly review recent preclinical data in support of RPPX, and discuss the current status of its clinical development.
authors.affiliation: Knopp Neurosciences, Inc., Pittsburgh, PA 15203, USA. valentin.gribkoff@knoppneurosciences.com
authors.forename: Valentin K
authors.initials: VK
authors.lastname: Gribkoff
authors.forename: Michael E
authors.initials: ME
authors.lastname: Bozik
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D052160:Benzothiazoles / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D018696:Neuroprotective Agents / Q000737:chemistry / Q000627:therapeutic use*; D000077487:Pramipexole; D013237:Stereoisomerism
chemical_list: D052160:Benzothiazoles; D018491:Dopamine Agonists; D018696:Neuroprotective Agents; D000077487:Pramipexole
references.citation: J Neurol. 2000 Mar;247 Suppl 1:I1-6
references.pmid: 10795881
references.citation: J Neurol. 2000 Mar;247 Suppl 1:I7-16
references.pmid: 10795882
references.citation: Science. 2000 Apr 21;288(5465):399
references.pmid: 10798964
references.citation: Biochem Soc Trans. 2000 Feb;28(2):170-7
references.pmid: 10816121
references.citation: Trends Biochem Sci. 2000 Jul;25(7):319-24
references.pmid: 10871882
references.citation: Brain Res. 2000 Jul 28;872(1-2):236-41
references.pmid: 10924701
references.citation: Cell Tissue Res. 2000 Jul;301(1):173-87
references.pmid: 10928290
references.citation: Neuroreport. 2000 Aug 3;11(11):2507-9
references.pmid: 10943712
references.citation: Biochem Soc Symp. 1999;66:167-79
references.pmid: 10989666
references.citation: FEBS Lett. 2000 Sep 29;482(1-2):6-12
references.pmid: 11018514
references.citation: J Neural Transm (Vienna). 2000;107(10):1165-73
references.pmid: 11129106
references.citation: Eur J Pharmacol. 2001 Apr 6;417(1-2):59-67
references.pmid: 11301060
references.citation: J Inherit Metab Dis. 2001 Apr;24(2):166-80
references.pmid: 11405338
references.citation: Eur J Pharmacol. 2001 Jun 22;422(1-3):209-16
references.pmid: 11430933
references.citation: Horm Metab Res. 2001 Sep;33(9):511-9
references.pmid: 11561209
references.citation: Nat Rev Neurosci. 2001 Nov;2(11):806-19
references.pmid: 11715057
references.citation: Neurobiol Dis. 2001 Dec;8(6):933-41
references.pmid: 11741389
references.citation: J Neurosci Res. 2002 Feb 15;67(4):494-500
references.pmid: 11835316
references.citation: Biochimie. 2002 Feb-Mar;84(2-3):153-66
references.pmid: 12022946
references.citation: Free Radic Biol Med. 2002 Aug 1;33(3):337-49
references.pmid: 12126755
references.citation: Proc Natl Acad Sci U S A. 2002 Dec 10;99 Suppl 4:16400-6
references.pmid: 12200548
references.citation: Free Radic Biol Med. 2002 Nov 15;33(10):1314-20
references.pmid: 12419463
references.citation: Clin Genet. 2003 Feb;63(2):83-101
references.pmid: 12630951
references.citation: J Biol Inorg Chem. 2003 Apr;8(4):373-80
references.pmid: 12644909
references.citation: Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3617-22
references.pmid: 12655070
references.citation: Curr Med Chem. 2003 Apr;10(8):649-61
references.pmid: 12678784
references.citation: Neurochem Res. 2003 Jul;28(7):1035-40
references.pmid: 12737528
references.citation: Curr Drug Targets CNS Neurol Disord. 2002 Oct;1(5):511-8
references.pmid: 12769603
references.citation: Eur J Pharmacol. 2003 Aug 15;475(1-3):29-35
references.pmid: 12954356
references.citation: Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):136-43
references.pmid: 13129799
references.citation: Anesth Analg. 2003 Oct;97(4):1020-4, table of contents
references.pmid: 14500151
references.citation: J Physiol. 2003 Oct 15;552(Pt 2):335-44
references.pmid: 14561818
references.citation: Neuropathol Appl Neurobiol. 2003 Dec;29(6):529-45
references.pmid: 14636160
references.citation: Neurologist. 2004 Jan;10(1):1-7
references.pmid: 14720310
references.citation: Biomed Pharmacother. 2004 Jan;58(1):39-46
references.pmid: 14739060
references.citation: Ann Neurol. 2004 Mar;55(3):306-19
references.pmid: 14991808
references.citation: FASEB J. 2004 May;18(7):869-71
references.pmid: 15033929
references.citation: Neuroscience. 2004;125(1):191-201
references.pmid: 15051158
references.citation: Eur J Med Chem. 2004 Mar;39(3):291-8
references.pmid: 15051178
references.citation: Annu Rev Neurosci. 2004;27:723-49
references.pmid: 15217349
references.citation: Free Radic Biol Med. 2004 Sep 15;37(6):755-67
references.pmid: 15304252
references.citation: J Bioenerg Biomembr. 2004 Aug;36(4):395-9
references.pmid: 15377878
references.citation: Annu Rev Cell Dev Biol. 2004;20:309-35
references.pmid: 15473843
references.citation: J Neurochem. 2004 Dec;91(5):1075-81
references.pmid: 15569251
references.citation: J Neurosci Res. 2005 Jan 1-15;79(1-2):231-9
references.pmid: 15573402
references.citation: Neurochem Res. 2004 Nov;29(11):1943-9
references.pmid: 15662830
references.citation: J Biol Chem. 2005 Apr 29;280(17):17266-74
references.pmid: 15691826
references.citation: Protein Sci. 2005 May;14(5):1201-13
references.pmid: 15840828
references.citation: J Neurol Sci. 2005 Jun 15;233(1-2):145-62
references.pmid: 15896810
references.citation: Arch Immunol Ther Exp (Warsz). 2005 May-Jun;53(3):213-25
references.pmid: 15995582
references.citation: J Neurosci. 2005 Jul 6;25(27):6449-59
references.pmid: 16000635
references.citation: Neurobiol Dis. 2006 Jan;21(1):228-36
references.pmid: 16111888
references.citation: Antioxid Redox Signal. 2005 Sep-Oct;7(9-10):1140-9
references.pmid: 16115017
references.citation: Exp Neurol. 2006 Mar;198(1):25-30
references.pmid: 16126198
references.citation: Trends Genet. 2005 Nov;21(11):583-6
references.pmid: 16154228
references.citation: J Pharmacol Exp Ther. 2006 Jan;316(1):189-99
references.pmid: 16188953
references.citation: Nat Rev Genet. 2005 Nov;6(11):815-25
references.pmid: 16304597
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2006 Jan;372(4):257-66
references.pmid: 16362428
references.citation: FASEB J. 2006 Mar;20(3):556-8
references.pmid: 16407457
references.citation: Biochim Biophys Acta. 2006 Feb;1757(2):79-89
references.pmid: 16473322
references.citation: Proc Natl Acad Sci U S A. 2006 May 2;103(18):7142-7
references.pmid: 16636275
references.citation: FEBS J. 2006 May;273(10):2077-99
references.pmid: 16649987
references.citation: Biochim Biophys Acta. 2006 Nov-Dec;1762(11-12):1013-24
references.pmid: 16675207
references.citation: Biochim Biophys Acta. 2006 May-Jun;1763(5-6):542-8
references.pmid: 16730811
references.citation: Antioxid Redox Signal. 2006 May-Jun;8(5-6):847-67
references.pmid: 16771675
references.citation: Biochim Biophys Acta. 2006 Nov-Dec;1762(11-12):1025-37
references.pmid: 16814528
references.citation: Curr Biol. 2006 Jul 25;16(14):R551-60
references.pmid: 16860735
references.citation: Neurodegener Dis. 2004;1(6):245-54
references.pmid: 16908975
references.citation: Neuron. 2006 Oct 5;52(1):39-59
references.pmid: 17015226
references.citation: Curr Alzheimer Res. 2006 Sep;3(4):339-49
references.pmid: 17017864
references.citation: Biochim Biophys Acta. 2006 Nov-Dec;1762(11-12):1150-7
references.pmid: 17071060
references.citation: Biochem Biophys Res Commun. 2006 Dec 22;351(3):602-11
references.pmid: 17084815
references.citation: Mol Membr Biol. 2006 Nov-Dec;23(6):521-30
references.pmid: 17127624
references.citation: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001447
references.pmid: 17253460
references.citation: Neuroscience. 2007 Apr 14;145(4):1233-48
references.pmid: 17303344
references.citation: Acta Neuropathol. 2007 May;113(5):535-42
references.pmid: 17333220
references.citation: Cell Death Differ. 2007 Jul;14(7):1261-6
references.pmid: 17464321
references.citation: Cell Death Differ. 2007 Aug;14(8):1529-41
references.pmid: 17464322
references.citation: Ann Neurol. 2007 May;61(5):427-34
references.pmid: 17469116
references.citation: Curr Opin Neurobiol. 2007 Jun;17(3):331-7
references.pmid: 17499497
references.citation: J Biol Inorg Chem. 2007 Aug;12(6):797-807
references.pmid: 17530304
references.citation: Acta Neuropathol. 2007 Jul;114(1):71-9
references.pmid: 17569066
references.citation: Cell Physiol Biochem. 2007;20(1-4):1-22
references.pmid: 17595511
references.citation: Curr Opin Investig Drugs. 2007 Jul;8(7):555-62
references.pmid: 17659475
references.citation: Am J Alzheimers Dis Other Demen. 2007 Aug-Sep;22(4):300-12
references.pmid: 17712161
references.citation: J Neurosci. 2007 Dec 19;27(51):13997-4006
references.pmid: 18094238
references.citation: Amyotroph Lateral Scler. 2008 Feb;9(1):50-8
references.pmid: 18270879
references.citation: Science. 2008 Mar 21;319(5870):1668-72
references.pmid: 18309045
references.citation: Lancet Neurol. 2008 May;7(5):409-16
references.pmid: 18396105
references.citation: Rev Neurol (Paris). 1991;147(6-7):417-30
references.pmid: 1962047
references.citation: J Med Chem. 1987 Mar;30(3):494-8
references.pmid: 3820220
references.citation: J Neuropathol Exp Neurol. 1985 Jul;44(4):430-8
references.pmid: 4040157
references.citation: J Neuropathol Exp Neurol. 1984 Sep;43(5):471-80
references.pmid: 6540800
references.citation: Eur J Pharmacol. 1995 Apr 24;277(2-3):209-14
references.pmid: 7493610
references.citation: Neuron. 1995 Jun;14(6):1105-16
references.pmid: 7605627
references.citation: Eur J Pharmacol. 1995 Jun 23;290(1):29-36
references.pmid: 7664822
references.citation: J Biol Chem. 1995 Feb 17;270(7):3234-8
references.pmid: 7852409
references.citation: J Bioenerg Biomembr. 1994 Oct;26(5):509-17
references.pmid: 7896766
references.citation: Hum Mol Genet. 1994 Jun;3(6):981-7
references.pmid: 7951249
references.citation: Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8292-6
references.pmid: 8058797
references.citation: Mol Pharmacol. 1994 May;45(5):1055-60
references.pmid: 8190096
references.citation: Ger J Ophthalmol. 1995 Nov;4(6):355-62
references.pmid: 8751101
references.citation: Neurol Clin. 1996 May;14(2):399-420
references.pmid: 8827179
references.citation: Neurology. 1996 Oct;47(4 Suppl 2):S54-61; discussion S61-2
references.pmid: 8858052
references.citation: Neurology. 1996 Oct;47(4 Suppl 2):S71-81; discussion S81-2
references.pmid: 8858055
references.citation: Neuropathol Appl Neurobiol. 1996 Oct;22(5):373-87
references.pmid: 8930947
references.citation: Neurology. 1996 Dec;47(6 Suppl 4):S233-41
references.pmid: 8959995
references.citation: Brain Res. 1996 Dec 2;742(1-2):80-8
references.pmid: 9117424
references.citation: Brain Res. 1997 Apr 18;754(1-2):181-6
references.pmid: 9134974
references.citation: Brain Res. 1997 May 9;756(1-2):247-55
references.pmid: 9187339
references.citation: J Pharmacol Exp Ther. 1997 Aug;282(2):707-14
references.pmid: 9262334
references.citation: J Pharmacol Exp Ther. 1997 Sep;282(3):1280-90
references.pmid: 9316836
references.citation: Arch Neurol. 1997 Oct;54(10):1246-50
references.pmid: 9341570
references.citation: Semin Neurol. 1998;18(1):27-39
references.pmid: 9562665
references.citation: J Neurochem. 1998 Jul;71(1):295-301
references.pmid: 9648878
references.citation: Biochim Biophys Acta. 1998 Aug 10;1366(1-2):139-49
references.pmid: 9714780
references.citation: Science. 1998 Sep 18;281(5384):1851-4
references.pmid: 9743498
references.citation: Exp Neurol. 1998 Sep;153(1):135-42
references.pmid: 9743575
references.citation: Ultrastruct Pathol. 1998 Sep-Oct;22(5):357-67
references.pmid: 9887478